Pneumococcal Conjugate Vaccine 13 (PCV-13)
A. Policy and Research Question
- What is the efficacy and effectiveness of PCV10 and PCV13 in reducing the incidence of invasive pneumococcal disease (IPD), clinical pneumonia, acute otitis media (AOM), inducing an immune response, and lowering pneumococcal nasopharyngeal (NP) carriage in children under 5 years old?
- Does PCV represent good value for money in the Philippines for preventing mortality and morbidity due to IPD, clinical pneumonia, and AOM for infants?
- What is the budget implication of using either PCV10 or PCV13 on the Expanded Program on Immunization (EPI) and the Philippine Health Insurance Corporation (PhilHealth) benefits programs?
- What are the ethical, legal, social, and health system implications of immunizing infants with either PCV10 or PCV13 to prevent mortality and morbidity due to IPD, clinical pneumonia, and AOM?
B. Protocol: Not available.
C. Reviewers: Health Technology Assessment Unit, DOH
D. Start of Review: May 29, 2020
E. End of Review: July 1, 2020
II. Initial findings of the Assessment for Public Consultation
III. Preliminary Recommendation
Preliminary recommendation: Completed
IV. Final Recommendation
Evidence summary: Not available. Link will be available soon.
Rapid review: Not available. Link will be available soon.
Decision of the Secretary of Health: http://bit.ly/DecisionPCV